Waldemar Wierzba has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Post-COVID-19 Thyroid Function Changes in Primary Care: A Retrospective Observational Study

    by Dorota Szydlarska, Marta Zuzanna Ciechomska, Andrzej Śliwczyński, Alicja Jakubowska, Waldemar Wierzba, Olga Maguza

    Background: Coronavirus disease 2019 (COVID-19) has been associated with thyroid dysfunction; however, evidence from primary care settings remains limited. Given that most patients with COVID-19 are managed outside hospital settings, understanding thyroid function changes in real-world primary care is clinically relevant. Methods: This retrospective study included 373 adult outpatients with confirmed COVID-19 and no prior thyroid disease, who were managed in a Family Medicine Clinic in Warsaw between January of 2022 and December of 2024. Thyroid function tests (yielding TSH, fT3, and fT4 levels) obtained within three months before and after infection were analyzed. Subacute thyroiditis (SAT) was assessed in symptomatic patients via thyroid ultrasound. Paired comparisons were performed, with p < 0.05 considered statistically significant. Results: A significant reduction in the mean TSH level was observed following COVID-19 compared with pre-infection values (mean 2.39 vs. 2.17 mIU/L; p < 0.05), while fT3 (2.93 vs. 2.98 pg/mL) and fT4 (1.31 vs. 1.30 ng/dL) concentrations remained unchanged. No significant associations were found between thyroid function changes and age or sex. Conclusions: In this real-world primary care population, lower TSH concentrations were observed following COVID-19 while peripheral thyroid hormone levels remained unchanged, suggesting predominantly modest changes in thyroid function parameters. Given the retrospective study design and the absence of a control group, these findings should be interpreted with caution. Further prospective studies are needed to clarify the clinical significance of post-COVID-19 thyroid function changes.

  • Open Access

    Concerns, Beliefs and Attitudes of Pharmacists About Medical Cannabis Use in Poland

    by Piotr Merks, Jameason Cameron, Justyna Kazmierczak, Artur Białkowski, Dariusz Świetlik, Mariola Borowska, Waldemar Wierzba, Urszula Bołkun-Skórnicka, Daniel Śliż, Eliza Blicharska, et al.

    Introduction: The global use of medical cannabis is steadily increasing. In Poland, medical cannabis was legalised in 2017; however, its use remains limited and not widely integrated into clinical practice. This study aimed to explore the attitudes, concerns, and beliefs of pharmacists and pharmacy students regarding the medical use of cannabis. Methods: A study was conducted in 2021 among 422 pharmacists and pharmacy students in Poland, primarily working in community pharmacies. Data were collected using a custom-designed questionnaire addressing beliefs, concerns, and professional experiences related to medical cannabis. Results: Nearly half of the respondents (48.9%) believe that cannabis should be used exclusively for medical purposes, while 47.6% support its use for both medical and recreational purposes following legalisation. A substantial majority (over 90%) consider cannabis effective for treating adults, with nearly 70% acknowledging its potential for treating children. Over 66% of respondents feel comfortable discussing medical cannabis with patients; however, fewer are confident in providing detailed advice about its use. The findings also highlight concerns about the long-term effects and potential legal implications of dispensing medical cannabis. Conclusions: Pharmacists and pharmacy students in Poland demonstrate openness to the medical use of cannabis and recognise its therapeutic potential. However, to enhance their ability to advise patients effectively, targeted educational initiatives are needed. These should focus on the clinical applications, safety, and long-term effects of cannabis, alongside strategies for addressing patient concerns and ensuring responsible usage.

  • Open Access

    Perception of Generic Drugs Among Pharmacists in Poland: The Role of Sociodemographic Factors in Shaping Professional Attitudes and Practices

    by Marcin Lewandowski, Urszula Religioni, Dariusz Świetlik, Adam Kobayashi, Marcin Czech, Piotr Wierzbiński, Daniel Śliż, Waldemar Wierzba, Katarzyna Plagens-Rotman, Piotr Merks

    Background: Pharmacists’ perceptions and practices shape the real-world uptake of generic medicines. From a health-economics perspective, wider generic substitution reduces patient out-of-pocket spending and creates headroom in payer budgets for high-value interventions. We assessed attitudes toward the efficacy, safety, and use of generics and examined sociodemographic correlates among Polish pharmacists. Methods: Analytical cross-sectional survey of licensed pharmacists in Poland was used (June–August 2025). The questionnaire covered reasons for recommending generics in long-term and single-use therapy; doubts about efficacy; views on bioequivalence testing; patient-reported experiences; and Likert-scale opinions on innovation, safety, efficacy, access, and payer savings. Associations were tested with χ2 and Mann–Whitney U (α = 0.05). Results: Of 342 respondents (67.5% women; 74.9% community pharmacists), cost was the leading reason to recommend generics in long-term therapy (91.0%), followed by efficacy (53.0%) and safety (51.5%); for single-use prescriptions, cost remained central (76.2%), with lower emphasis on efficacy (47.5%) and safety (45.0%). Pharmacists who never recommend generics were older and more experienced (p = 0.006; p = 0.012). Doubts about generic efficacy were reported by 36.2% overall and more often among women, hospital pharmacists, and those with a specialization; 53.5% of those with doubts would advise switching even to a costlier option. Nearly half supported conducting bioequivalence studies between generics (49.6%). Positive perceptions predominated: 82.9% agreed generics are as effective and 84.6% as safe as originators. Most endorsed system benefits, including payer savings enabling list expansion (73.6%) and improved patient access (92.5%); agreement on access was higher among community pharmacists (p = 0.004). Conclusions: Polish pharmacists largely view generics as clinically equivalent and system-enhancing, with cost the dominant driver of recommendation. Targeted education—especially for hospital settings and specialized pharmacists—and attention to patient-reported experiences may further strengthen confidence and appropriate use of generics.